Table 1 Clinical findings and treatments of 27 colorectal T/NK cell lymphoma patients
From: Endoscopic and clinicopathological characteristics of colorectal T/NK cell lymphoma
| Clinical subtype | MEITL | ATLL | Other group | Total |
|---|---|---|---|---|
| No. of cases | 9 (33%) | 11 (41%) | 7 (26%) | 27 |
| Median age (range), y | 63 (47–84) | 64 (50–74) | 54 (43–69) | 60 (43–84) |
| Male: female | 6:3 | 7:4 | 6:1 | 19:8 |
| Past history of UC | 1 (11%) | 0 | 1 (14%) | 2 (7%) |
| Chronic diarrhea | 5 (56%) | 4 (36%) | 2 (29%) | 11 (41%) |
| Abdominal pain | 4 (44%) | 3 (27%) | 4 (57%) | 11 (41%) |
| Weight loss | 4 (44%) | 2 (18%) | 0 | 6 (22%) |
| Fever | 0 | 2 (18%) | 2 (29%) | 4 (15%) |
| Total protein (g/dl) | 5.7 (4–6.6) | 6.3 (5.4–7.2) | 7.5 (5.9–8.4) | 6.5 (4–8.4) |
| Albumin (g/dl) | 3.1 (2.1–3.8) | 3.4 (2.6–4) | 3.9 (2.7–4.4) | 3.5 (2.1–4.4) |
| LDH (U/l) | 191 (112–288)* | 785 (262–2192)* | 184 (123–244) | 387 (112–2192) |
| sIL-2R (U/ml) | 1815 (587–4410)* | 51,643 (3501–154,246)* | 10,993 (1330–25,818) | 21,484 (587–154,246) |
| Leukemic change | 2 (22%)** | 6/8 (75%)** | 1 (14%) | 9/21 (43%) |
| Clinical stage I | 2 (22%) | 0 | 2 (29%) | 4 (15%) |
| II (II1, II2, IIE) | 3 (33%) | 1 (9%) | 2 (29%) | 6 (22%) |
| II1 | 1 (11%) | 0 | 1 (14%) | 2 (7%) |
| II2 | 1 (11%) | 0 | 0 | 1 (4%) |
| IIE | 1 (11%) | 1 (9%) | 1 (14%) | 3 (11%) |
| IV | 4 (44%)** | 10 (91%)** | 3 (42%) | 17 (63%) |
| Surgery | 1 (11%) | 0 | 2 (29%) | 3 (11%) |
| Surgery and chemotherapy | 3 (33%) | 1 (9%) | 0 | 4 (15%) |
| Chemotherapy | 2 (22%)** | 9 (82%)** | 3 (42%) | 14 (52%) |
| Chemotherapy and SCT | 2 (22%) | 1 (9%) | 0 | 3 (11%) |
| No treatment | 1 (11%) | 0 | 2 (29%) | 3 (11%) |